Clinical trials: Leukemia, Myeloid, Chronic
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06543381
- Testing
- Biospecimen Collection, Olutasidenib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
- Trial name
- NCT04233346
- Testing
- Ponatinib 30mg OD, Ponatinib 45mg OD
- Where
- 14 sites in China
- Volunteers
- 93 people
- Sponsor
- Otsuka Beijing Research Institute
Chronic Myeloid Leukaemia
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib.
- Trial name
- NCT05682924
- Testing
- taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
- Where
- 2 sites in Russia
- Volunteers
- 105 people
- Sponsor
- Samara State Medical University
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.
- Conditions
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
- Trial name
- CARDINAL (NCT06163430)
- Testing
- MK-4208
- Where
- 54 sites in United States, Australia and 7 more
- Volunteers
- 330 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
This clinical trial evaluates the safety and effectiveness of adding itacitinib to cyclophosphamide and tacrolimus for the prevention of graft versus host disease (GVHD) in patients undergoing hematopoietic stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05364762
- Testing
- Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloid Leukemia (CML)
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy
Chronic myeloid leukaemia (CML) is a blood cancer with an annual worldwide incidence of 1/100,000 population. Imatinib is used for the treatment of CML and has significantly improved the management of the disease.
- Trial name
- NCT07022743
- Testing
- Imatinib, Artesunate
- Where
- Nigeria
- Volunteers
- 75 people
- Sponsor
- Obafemi Awolowo University
Chronic Myeloid Leukemia
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the stage of the disease, via pharmaceutical…
- Trial name
- PHARM-LMC (NCT05130138)
- Testing
- Pharmaceutical intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Chronic Myeloid Leukemia
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
- Trial name
- NCT06236724
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
- Trial name
- NCT07269470
- Testing
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.
- Conditions
- Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia
- Trial name
- NCT03934372
- Testing
- Ponatinib
- Where
- 23 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Incyte Biosciences International Sàrl
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia
- Trial name
- HAPLOTAB (NCT05236764)
- Testing
- CliniMACS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic…
- Conditions
- Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT07582172
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloid Leukemia, Chronic Phase
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
The purpose of the present study is to determine the rate of successful treatment-free remission (TFR) within the first 52 weeks following cessation of ponatinib treatment in patients who achieved MR4.
- Trial name
- ResToP (NCT04160546)
- Testing
- Ponatinib 15 MG, Acetylsalicylic acid 100 MG
- Where
- 13 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Leukemia, Chronic Myeloid
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously…
- Trial name
- ASC2ADHERE (NCT07549516)
- Where
- 69 sites in Germany
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT01424982
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04140487
- Testing
- Azacitidine, Gilteritinib, Venetoclax
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04256317
- Testing
- Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine
- Where
- 73 sites in United States, Canada and 8 more
- Volunteers
- 316 people
- Sponsor
- Taiho Oncology, Inc.
Hematologic Malignancy, Bone Marrow Transplant Rejection
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor…
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT06398457
- Testing
- Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Patients will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, patients will be given very strong doses of chemotherapy, which will kill all their existing stem cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia
- Trial name
- DOTTI (NCT01494103)
- Testing
- iCaspase9-transduced T cells, AP1903
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase.
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT05007873
- Testing
- Dasatinib, Decitabine and Cedazuridine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center